About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

Johnson & Johnson (JNJ.N): The Duplex-AD Phase 2b proof-of-concept study for the treatment of moderate to severe atopic dermatitis did not meet its efficacy target.

2025-12-26

Johnson & Johnson (JNJ.N): The Duplex-AD Phase 2b proof-of-concept study for the treatment of moderate to severe atopic dermatitis did not meet its efficacy target.

Other News
2025-12-26

1. The Japanese Cabinet approved a record initial budget of 122.3 trillion yen for fiscal year 2026. 2. Japanese Finance Minister Satsuki Katayama: Japan will not rely on easily issuing Japanese government bonds. 3. Thai Ministry of Commerce: The T

1. The Japanese Cabinet approved a record initial budget of 122.3 trillion yen for fiscal year 2026. 2. Japanese Finance Minister Satsuki Katayama: Japan will not rely on easily issuing Japanese government bonds. 3. Thai Ministry of Commerce: The Thai baht should maintain competitiveness and stability. 4. Syrian Central Bank Governor: January 1st is the launch date for currency swaps, part of a plan to issue new banknotes. 5. The Central Bank of Egypt implemented its fifth interest rate cut this year, with unexpectedly slowing inflation opening up policy space. 6. The Central Bank of Russia announced its foreign exchange intervention plan for the first half of 2026, stating that in addition to separate interventions on behalf of the Ministry of Finance, it will sell 4.62 billion rubles worth of foreign exchange daily.
2025-12-27

The governor of the Central Bank of Uruguay has hinted at further interest rate cuts in 2026.

The governor of the Central Bank of Uruguay has hinted at further interest rate cuts in 2026.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2025 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.

Web Design by YSD